Emcure Pharmaceuticals Ltd (NSE:EMCURE)

Q1 2026 Emcure Pharmaceuticals Ltd Earnings Call Transcript

Aug 7, 2025 / 10:00 AM GMT

Release Date Price: ₹1400.7 (-1.52%)

Transcript

Key Points

Positve

Emcure Pharmaceuticals Ltd (BOM:544210) reported a strong start to the fiscal year with a 15.7% year-on-year revenue growth and a 20% increase in EBITA.
The company achieved a 41% growth in profit after tax, reaching its highest quarterly profits of 215 crores.
The domestic business outpaced industry growth, with significant contributions from gynec, cardiac, anti-infective, and vitamins therapies.
International business grew by 20%, with notable performance in Canada and emerging markets, driven by market share gains and new product launches.
The company is expanding its partnership with Sanofi, enhancing its presence in the diabetes and cardiovascular segments.

Negative

The company faces challenges in the institutional segment, particularly with pricing competition.
There is uncertainty regarding the impact of tariffs on exports, although the company's exposure to the US market is minimal.
The emerging markets' growth is contingent on winning tenders and obtaining product registrations, which introduces an element of unpredictability.
The company is in the investment phase for its consumer wellness and dermatology initiatives, which may take time to become significant contributors.
There is a potential risk of funding constraints for ARV products due to reduced contributions from major donors like the US.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EMCU.NS - Emcure Pharmaceuticals Ltd
Q1 2026 Emcure Pharmaceuticals Ltd Earnings Call
Aug 07, 2025 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to MTO Pharmaceuticals Limited Q1 FY26 earnings conference call.

As a reminder, our participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing, then 0 on your touch home phone. Please note that this conference is being recorded.

Today we have on call Mr. Satish Mehta, CEO, Mr. Sammit Mehta, executive director, Mr. Vikas Thaper, President Corporate Development strategy and Finance, Mr. Tajuddin Sheikh, CFO, Mr. Pushnahar, EVP corporate Development and strategy.

I now hand over

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.